Immatics - About the company
Immatics is a public company based in Tubingen (Germany), founded in 2000 by Harpreet Singh. It operates as a Developer of T -cell-based immunotherapies for the treatment of cancer. Immatics has raised $236M in funding from investors like Wellington Partners Venture Capital, 3i Group and Dievini. The company has 3337 active competitors, including 1149 funded and 798 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio.
Company Details
Developer of T -cell-based immunotherapies for the treatment of cancer. The company has propriety platform XPRESIDENT is involved in identifying and validating antigens specific to cancer cells and subsequently develops adoptive cell therapies and bispecific TCRs for treating cancer. IMA101, using its proprietary ACTolog approach, which is T-cell products generated from peripheral blood cells with defined target selectivity.
- Website
- immatics.com
- Social
- Email ID
- *****@immatics.com
- Phone Number
- +49 **********
- Registered Address
- Houston, Texas
Key Metrics
Founded Year
2000
Location
Tubingen, Germany
Stage
Public
Total Funding
$236M in 9 rounds
Latest Funding Round
Investors
Ranked
46th among 3337 active competitors
Employee Count
646 as on Jul 31, 2026
Similar Companies
Exit Details
Public
Legal entities associated with Immatics
Immatics is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
IMMATICS US INC CIN: 472194527 , United States, Active | Dec 31, 1999 | - | 261 (As on Dec 31, 2024) | - |
Immatics's IPO details
Immatics got listed on Jul 02, 2020.
Click here to take a look at Immatics's IPO in detail
Sign up to download Immatics' company profile
Immatics's funding and investors
Immatics has raised a total funding of $236M over 9 rounds. Its first funding round was on Mar 2004. Its latest funding round was a Post IPO round on Jul 24, 2023 for $*****. 1 investor participated in its latest round. Immatics has 20 institutional investors.
Here is the list of recent funding rounds of Immatics:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jul 24, 2023 | 8399254 | Post IPO | 7225901 | 7409800 | 9761575 | 7197264 |
Aug 05, 2020 | 8827001 | Post IPO | 2298992 | 1978016 | 3318245 | |
Oct 04, 2017 | 1746735 | Series E | 2034827 | 3349874 |
Access funding benchmarks and valuations. Sign up today!View details of Immatics's funding rounds and investors
Immatics' founders and board of directors
Founder? Claim ProfileThe founders of Immatics is Harpreet Singh.
Here are the details of Immatics' key team members:
- Harpreet Singh: Co-Founder & CEO & MD of Immatics and founder of 1 other company.
View details of Immatics's Founder profiles and Board Members
Immatics' employee count trend
Immatics has 646 employees as of Jul 26. Here is Immatics's employee count trend over the years:
Uncover Immatics' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Immatics's Competitors and alternates
Top competitors of Immatics include Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio. Here is the list of Top 10 competitors of Immatics, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 82/100 | |
2nd |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 75/100 | |
3rd | Senti Bio 2016, San Francisco (United States), Public | Developer of cell and gene therapies for patients living with incurable diseases | $158M | 72/100 | |
4th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 72/100 | |
5th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
6th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
7th | Karyopharm 2008, Newton (United States), Public | Biopharmaceutical company focused on developing and commercializing innovative cancer therapies | $98.4M | 71/100 | |
8th |  Moderna 2010, Cambridge (United States), Public | Developer of mRNA-based therapeutics for a wide range of diseases | $2.78B | 71/100 | |
9th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 71/100 | |
10th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 71/100 | ||
46th | Developer of T -cell-based immunotherapies for the treatment of cancer | $236M | 67/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Immatics's competitors? Click here to see the top ones
Immatics's Investments and acquisitions
Immatics has made no investments or acquisitions yet.
Reports related to Immatics
Here is the latest report on Immatics's geography:
News related to Immatics
Filter this listMedia has covered Immatics for a total of 16 events in the last 1 year, 8 of them have been about company updates and 2 about people movement.
•
•
Moderna's Acquisition Currency Strengthened, Potential Targets IdentifiedWall St.•Aug 20, 2026•Immatics
•
Immatics Announces Second Quarter 2026 Financial Results and Business UpdateGlobeNewswire•Aug 18, 2026•Immatics
•
Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026GlobeNewswire•Jul 17, 2026•Immatics
•
•
Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Gynecologic CancersGlobeNewswire•May 30, 2026•Immatics
•
Immatics Announces First Quarter 2026 Financial Results and Business UpdateGlobeNewswire•May 12, 2026•Immatics
•
Cellular Origins, Immatics Partner for Automated Cell Therapy ManufacturingContract Pharma•May 05, 2026•Cellular Origins, Immatics
•
Immatics Announces Four Oral Presentations at 2026 ASCO Annual MeetingGlobeNewswire•Apr 21, 2026•Immatics
•
Immatics' PRAME-directed Cell Therapy Induces Remission in Pediatric Cancer PatientGlobeNewswire•Apr 18, 2026•Immatics
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Immatics
Explore our recently published companies
- Wisdom Square Technologies - New Hyde Park based, 2008 founded, Unfunded company
- Fruverpack - Almoradi based, 1992 founded, Unfunded company
- AERA - Bouxwiller based, 1979 founded, Unfunded company
- Divine Hindu - Ujjain based, 2023 founded, Unfunded company
- Globaldigitalpartner.com - 2013 founded, Unfunded company
- OROK - Bourgoin Jallieu based, 2018 founded, Deadpooled company
